Viamet Pharmaceuticals Secures $60,000,000 Series D Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=647fc483-5d57-4942-8954-18f506244152
Date
10/21/2014
Company Name
Viamet Pharmaceuticals
Mailing Address
4505 Emperor Blvd. Durham, NC 27703 USA
Company Description
Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology.
Website
http://www.viamet.com
Transaction Type
Venture Equity
Transaction Amount
$60,000,000
Transaction Round
Series D
Proceeds Purposes
l compounds, as well as to initiate new research programs supported by the company’s Metallophile® platform. The financing is expected to provide sufficient capital to fund operations through the achievement of several important clinical milestones over the next number of years.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor